Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Cornelia Liedtke"'
Autor:
A. Kohls, Hans-Peter Fischer, Ronald E. Kates, Matthias Christgen, Michael Braun, T. Reimer, Hans Heinrich Kreipe, Nadia Harbeck, Jochem Potenberg, Katja Krauss, E-M. Grischke, Andrea Stefek, Helmut Forstbauer, O Gluz, Doris Augustin, Ulrike Nitz, Claudia Schumacher, Johannes Schumacher, Cornelia Liedtke, Sherko Kuemmel, Rachel Wuerstlein
Publikováno v:
Annals of Oncology. 28:2768-2772
Response rates in HER2-overexpressing EBC treated with neoadjuvant chemotherapy and trastuzumab (T) have been improved by addition of pertuzumab (P). The prospective, phase II, neoadjuvant WSG-ADAPT HER2+/HR- trial assessed whether patients with stro
Autor:
Birgit Pott, Markus Wallwiener, Johannes Ettl, Rüdiger Schulz-Wendtland, Leyla Akpolat-Basci, Erik Belleville, Alexander Hein, Diana Lüftner, Florin-Andrei Taran, Dirk Pott, Peyman Hadji, Wolfgang Janni, Hans Tesch, Naiba Nabieva, Andreas Schneeweiss, Hans-Christian Kolberg, Thomas Geyer, Hanna Einarson, Michael P. Lux, Bernhard Volz, Andreas D. Hartkopf, Michael Untch, Lothar Häberle, Cornelia Liedtke, Volkmar Müller, Sarah Wetzig, Peter A. Fasching, Harald Seeger, Diethelm Wallwiener, Sara Y. Brucker, Friedrich Overkamp, Arndt Hartmann, Matthias W. Beckmann, Tanja Fehm, Paul Gass
Publikováno v:
Breast cancer research and treatment. 173(2)
Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM).
Autor:
Hans Holger Fischer, Doris Augustin, Helmut Forstbauer, Rachel Wuerstlein, Matthias Christgen, Eva-Maria Grischke, Ulrike Nitz, Andrea Stefek, Hans Kreipe, Cornelia Liedtke, Michael Braun, Sherko Kümmel, Claudia Schumacher, A. Kohls, Jochem Potenberg, Toralf Reimer, Oleg Gluz, Katja Krauss, Nadia Harbeck
Publikováno v:
Journal of Clinical Oncology. 34:518-518
518Background: In HER2+ EBC pCR rates after neoadjuvant chemo (CT)+/- anti-HER2 therapy differ according to hormone receptor (HR) status. The neoadjuvant ADAPT HER2+/HR- phase II trial aims to iden...